Related Experiment Video

Updated: Aug 1, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.8K

Risk of Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic Approach, and Management

Henry Sutanto1,2, Gatot Soegiarto1,2,3

  • 1Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia.

Hematology Reports
|April 24, 2023
PubMed

Insights

Coronavirus disease 2019 (COVID-19) significantly elevates the risk of dangerous blood clots (thromboembolism), impacting survival and long-term health. Understanding COVID-19

Area of Science:

  • Medical Research
  • Infectious Diseases
  • Cardiovascular Science

Background:

  • Coronavirus disease 2019 (COVID-19) is linked to an increased risk of thromboembolic events.
  • Severe COVID-19 infections requiring intensive care heighten this risk.
  • Thromboembolic complications in COVID-19 patients correlate with higher mortality and reduced quality of life.

Purpose of the Study:

  • To comprehensively review the pathogenesis of thrombosis in COVID-19.
  • To discuss clinical manifestations and diagnostic markers of COVID-19-associated thromboembolism.
  • To explain preventive and therapeutic strategies for thromboembolism during and after COVID-19 infection.

Main Methods:

  • Literature review focusing on COVID-19 pathophysiology.
  • Analysis of molecular and cellular mechanisms of COVID-19-associated thrombosis.
  • Discussion of clinical data on venous and arterial thromboembolism in COVID-19 patients.

Main Results:

  • COVID-19 infection presents specific clinical characteristics and underlying pathophysiology contributing to thrombosis.
  • Detailed review of molecular and cellular pathways involved in COVID-19-related blood clot formation.
  • Clinical manifestations and potential diagnostic markers for thromboembolism in COVID-19 are explored.

Conclusions:

  • Understanding COVID-19 thrombosis pathogenesis is crucial for prevention and treatment.
  • Effective management strategies are needed to reduce morbidity, mortality, and disability associated with COVID-19 thromboembolism.
  • The risk of thromboembolism persists long after acute COVID-19 infection, necessitating ongoing vigilance.

Keywords:
COVID-19coagulationcoronavirusdeep-vein thrombosispulmonary embolismthromboembolism

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.7K

Related Concept Videos

Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
12.1K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
17
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
14
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
12
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
782